Lenvatinib is an oral kinase inhibitor that selectively inhibits receptor tyrosine kinases involved in tumor angiogenesis and tumor growth (e.g., VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor (FGFR)1, FGFR2, FGFR3, FGFR4, PDGFRα, KIT, and RET) [34,35]. This evidence concerns the gene FGFR2 and neoplasm.